The AHSG Knockout HT29 Polyclonal Cells product constitutes a CRISPR/Cas9-edited polyclonal knockout cell population in which the AHSG gene has been disrupted to generate a loss-of-function model. This polyclonal format provides a heterogeneous population of HT29 cells carrying diverse edits within the AHSG locus, enabling functional studies without single-cell clonal selection. The knockout cell population is designed for researchers requiring a robust, scalable tool to interrogate AHSG-dependent mechanisms in a human colorectal adenocarcinoma background. By abolishing fetuin-A expression, this model facilitates investigation of its regulatory roles in insulin signaling, TGF-beta superfamily pathways, and mineralization control. The cells are maintained under standard culture conditions and are suitable for a wide array of molecular and cellular assays.
The parental HT29 cell line is a well-characterized human colorectal adenocarcinoma line derived from a primary colon tumor, exhibiting epithelial morphology and commonly employed as an in vitro model for intestinal epithelial biology and colorectal cancer. HT29 cells retain key signaling pathways relevant to colon carcinogenesis, including insulin and TGF-beta cascades, and are capable of differentiation and mucin production under appropriate conditions. Their use in this knockout context permits dissection of AHSG function within a colon cancer epithelial environment, where metabolic dysregulation and aberrant signaling are hallmarks. The cells provide a physiologically relevant platform for studying how fetuin-A loss impacts colorectal tumor cell behavior and disease-relevant processes.
AHSG encodes the hepatic glycoprotein fetuin-A, a negative acute-phase reactant and systemic inhibitor of ectopic calcification. Mechanistically, fetuin-A binds to the insulin receptor and suppresses its tyrosine kinase activity, thus attenuating insulin-stimulated autophosphorylation and downstream IRS1/AKT signaling. In parallel, it modulates TGF-beta receptor I activation and subsequent SMAD2/3 phosphorylation. The mechanistic summary provided indicates that AHSG knockout in HT29 cells eliminates inhibition of both insulin receptor tyrosine kinase and TGF-beta receptor signaling, potentially enhancing AKT and SMAD phosphorylation, altering lipid metabolism, and disrupting mineralization regulatory processes. Key upstream regulators include TNF-alpha, IL-6, insulin, and glucocorticoids, while downstream targets encompass IRS1, AKT, SMAD2/3, and TGFBR1. Fetuin-A interacts directly with the insulin receptor, TGFBR1, calcium ions, phosphate, matrix Gla protein (MGP), and apolipoprotein A-I (APOA1). Representative pathway components involved in signaling networks include INSR, IRS1, AKT1, TGFB1, TGFBR1, SMAD2, SMAD3, MGP, and ALP, highlighting the cross-talk between metabolic and TGF-beta pathways.
In the context of HT29 colorectal cancer cells, the AHSG knockout model holds particular significance for understanding how fetuin-A loss influences insulin resistance and cancer progression. Colorectal tumors often exhibit altered insulin/IGF-1 signaling and TGF-beta pathway activity, which can drive proliferation, survival, and metastasis. By removing a critical negative regulator of these pathways, researchers can examine the consequences on cellular metabolism, phosphorylation cascades, and mineralization balance within an epithelial tumor setting. Furthermore, since fetuin-A is a systemic inhibitor of calcium phosphate deposition, its deletion may unmask ectopic calcification tendencies in colon cancer cells, providing a unique opportunity to study the interplay between cancer and mineral homeostasis. This model thus bridges systemic metabolic regulators and local tumor signaling, facilitating investigation of disease mechanisms associated with type 2 diabetes, cardiovascular calcification, and non-alcoholic fatty liver disease, all of which are linked to AHSG dysfunction.
Typical research applications for these polyclonal knockout cells include probing insulin resistance mechanisms in colorectal cancer via insulin-stimulated glucose uptake assays and phospho-AKT western blotting; interrogating TGF-beta/SMAD signaling through phospho-SMAD2/3 analysis and RT-qPCR of target genes; modeling ectopic calcification with Alizarin Red S staining; and conducting comprehensive metabolic assays using Seahorse technology. The cells are also well-suited for proliferation, migration, and invasion studies to assess phenotypic changes, co-immunoprecipitation of AHSG-interacting proteins such as the insulin receptor and TGFBR1, and drug sensitivity screens targeting insulin/TGF-beta crosstalk. Transcriptomic profiling via RNA-seq can further elucidate global gene expression changes. For additional technical information or assistance with experimental design, please contact Ascent Research.
